2011 Focused update of 2009 American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer

Christopher G. Azzoli, Sarah Temin, Timothy Aliff, Sherman Baker, Julie Brahmer, David H. Johnson, Janessa L. Laskin, Gregory Masters, Daniel Milton, Luke Nordquist, William Pao, David G. Pfister, Steven Piantadosi, Joan H. Schiller, Reily Smith, Thomas J. Smith, John R. Strawn, David Trent, Giuseppe Giaccone

Research output: Contribution to journalArticle

228 Citations (Scopus)

Abstract

Purpose: An American Society of Clinical Oncology (ASCO) focused update updates a single recommendation (or subset of recommendations) in advance of a regularly scheduled guideline update. This document updates one recommendation of the ASCO Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer (NSCLC) regarding switch maintenance chemotherapy. Clinical Context: Recent results from phase III clinical trials have demonstrated that in patients with stage IV NSCLC who have received four cycles of first-line chemotherapy and whose disease has not progressed, an immediate switch to alternative, single-agent chemotherapy can extend progression-free survival and, in some cases, overall survival. Because of limitations in the data, delayed treatment with a second-line agent after disease progression is also acceptable. Recent Data: Seven randomized controlled trials of carboxyaminoimidazole, docetaxel, erlotinib, gefitinib, gemcitabine, and pemetrexed have evaluated outcomes in patients who received an immediate, non-cross resistant alternative therapy (switch maintenance) after first-line therapy. Recommendation: In patients with stage IV NSCLC, first-line cytotoxic chemotherapy should be stopped at disease progression or after four cycles in patients whose disease is stable but not responding to treatment. Two-drug cytotoxic combinations should be administered for no more than six cycles. For those with stable disease or response after four cycles, immediate treatment with an alternative, single-agent chemotherapy such as pemetrexed in patients with nonsquamous histology, docetaxel in unselected patients, or erlotinib in unselected patients may be considered. Limitations of this data are such that a break from cytotoxic chemotherapy after a fixed course is also acceptable, with initiation of second-line chemotherapy at disease progression.

Original languageEnglish (US)
Pages (from-to)3825-3831
Number of pages7
JournalJournal of Clinical Oncology
Volume29
Issue number28
DOIs
StatePublished - Oct 1 2011
Externally publishedYes

Fingerprint

Practice Guidelines
Non-Small Cell Lung Carcinoma
Drug Therapy
docetaxel
Pemetrexed
Disease Progression
gemcitabine
Maintenance Chemotherapy
Guidelines
Phase III Clinical Trials
Medical Oncology
Drug Combinations
Therapeutics
Complementary Therapies
Disease-Free Survival
Histology
Randomized Controlled Trials
Maintenance
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

2011 Focused update of 2009 American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. / Azzoli, Christopher G.; Temin, Sarah; Aliff, Timothy; Baker, Sherman; Brahmer, Julie; Johnson, David H.; Laskin, Janessa L.; Masters, Gregory; Milton, Daniel; Nordquist, Luke; Pao, William; Pfister, David G.; Piantadosi, Steven; Schiller, Joan H.; Smith, Reily; Smith, Thomas J.; Strawn, John R.; Trent, David; Giaccone, Giuseppe.

In: Journal of Clinical Oncology, Vol. 29, No. 28, 01.10.2011, p. 3825-3831.

Research output: Contribution to journalArticle

Azzoli, CG, Temin, S, Aliff, T, Baker, S, Brahmer, J, Johnson, DH, Laskin, JL, Masters, G, Milton, D, Nordquist, L, Pao, W, Pfister, DG, Piantadosi, S, Schiller, JH, Smith, R, Smith, TJ, Strawn, JR, Trent, D & Giaccone, G 2011, '2011 Focused update of 2009 American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer', Journal of Clinical Oncology, vol. 29, no. 28, pp. 3825-3831. https://doi.org/10.1200/JCO.2010.34.2774
Azzoli, Christopher G. ; Temin, Sarah ; Aliff, Timothy ; Baker, Sherman ; Brahmer, Julie ; Johnson, David H. ; Laskin, Janessa L. ; Masters, Gregory ; Milton, Daniel ; Nordquist, Luke ; Pao, William ; Pfister, David G. ; Piantadosi, Steven ; Schiller, Joan H. ; Smith, Reily ; Smith, Thomas J. ; Strawn, John R. ; Trent, David ; Giaccone, Giuseppe. / 2011 Focused update of 2009 American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. In: Journal of Clinical Oncology. 2011 ; Vol. 29, No. 28. pp. 3825-3831.
@article{9025eab5c9cd45c9b5e2a3ca413b1dc6,
title = "2011 Focused update of 2009 American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer",
abstract = "Purpose: An American Society of Clinical Oncology (ASCO) focused update updates a single recommendation (or subset of recommendations) in advance of a regularly scheduled guideline update. This document updates one recommendation of the ASCO Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer (NSCLC) regarding switch maintenance chemotherapy. Clinical Context: Recent results from phase III clinical trials have demonstrated that in patients with stage IV NSCLC who have received four cycles of first-line chemotherapy and whose disease has not progressed, an immediate switch to alternative, single-agent chemotherapy can extend progression-free survival and, in some cases, overall survival. Because of limitations in the data, delayed treatment with a second-line agent after disease progression is also acceptable. Recent Data: Seven randomized controlled trials of carboxyaminoimidazole, docetaxel, erlotinib, gefitinib, gemcitabine, and pemetrexed have evaluated outcomes in patients who received an immediate, non-cross resistant alternative therapy (switch maintenance) after first-line therapy. Recommendation: In patients with stage IV NSCLC, first-line cytotoxic chemotherapy should be stopped at disease progression or after four cycles in patients whose disease is stable but not responding to treatment. Two-drug cytotoxic combinations should be administered for no more than six cycles. For those with stable disease or response after four cycles, immediate treatment with an alternative, single-agent chemotherapy such as pemetrexed in patients with nonsquamous histology, docetaxel in unselected patients, or erlotinib in unselected patients may be considered. Limitations of this data are such that a break from cytotoxic chemotherapy after a fixed course is also acceptable, with initiation of second-line chemotherapy at disease progression.",
author = "Azzoli, {Christopher G.} and Sarah Temin and Timothy Aliff and Sherman Baker and Julie Brahmer and Johnson, {David H.} and Laskin, {Janessa L.} and Gregory Masters and Daniel Milton and Luke Nordquist and William Pao and Pfister, {David G.} and Steven Piantadosi and Schiller, {Joan H.} and Reily Smith and Smith, {Thomas J.} and Strawn, {John R.} and David Trent and Giuseppe Giaccone",
year = "2011",
month = "10",
day = "1",
doi = "10.1200/JCO.2010.34.2774",
language = "English (US)",
volume = "29",
pages = "3825--3831",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "28",

}

TY - JOUR

T1 - 2011 Focused update of 2009 American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer

AU - Azzoli, Christopher G.

AU - Temin, Sarah

AU - Aliff, Timothy

AU - Baker, Sherman

AU - Brahmer, Julie

AU - Johnson, David H.

AU - Laskin, Janessa L.

AU - Masters, Gregory

AU - Milton, Daniel

AU - Nordquist, Luke

AU - Pao, William

AU - Pfister, David G.

AU - Piantadosi, Steven

AU - Schiller, Joan H.

AU - Smith, Reily

AU - Smith, Thomas J.

AU - Strawn, John R.

AU - Trent, David

AU - Giaccone, Giuseppe

PY - 2011/10/1

Y1 - 2011/10/1

N2 - Purpose: An American Society of Clinical Oncology (ASCO) focused update updates a single recommendation (or subset of recommendations) in advance of a regularly scheduled guideline update. This document updates one recommendation of the ASCO Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer (NSCLC) regarding switch maintenance chemotherapy. Clinical Context: Recent results from phase III clinical trials have demonstrated that in patients with stage IV NSCLC who have received four cycles of first-line chemotherapy and whose disease has not progressed, an immediate switch to alternative, single-agent chemotherapy can extend progression-free survival and, in some cases, overall survival. Because of limitations in the data, delayed treatment with a second-line agent after disease progression is also acceptable. Recent Data: Seven randomized controlled trials of carboxyaminoimidazole, docetaxel, erlotinib, gefitinib, gemcitabine, and pemetrexed have evaluated outcomes in patients who received an immediate, non-cross resistant alternative therapy (switch maintenance) after first-line therapy. Recommendation: In patients with stage IV NSCLC, first-line cytotoxic chemotherapy should be stopped at disease progression or after four cycles in patients whose disease is stable but not responding to treatment. Two-drug cytotoxic combinations should be administered for no more than six cycles. For those with stable disease or response after four cycles, immediate treatment with an alternative, single-agent chemotherapy such as pemetrexed in patients with nonsquamous histology, docetaxel in unselected patients, or erlotinib in unselected patients may be considered. Limitations of this data are such that a break from cytotoxic chemotherapy after a fixed course is also acceptable, with initiation of second-line chemotherapy at disease progression.

AB - Purpose: An American Society of Clinical Oncology (ASCO) focused update updates a single recommendation (or subset of recommendations) in advance of a regularly scheduled guideline update. This document updates one recommendation of the ASCO Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer (NSCLC) regarding switch maintenance chemotherapy. Clinical Context: Recent results from phase III clinical trials have demonstrated that in patients with stage IV NSCLC who have received four cycles of first-line chemotherapy and whose disease has not progressed, an immediate switch to alternative, single-agent chemotherapy can extend progression-free survival and, in some cases, overall survival. Because of limitations in the data, delayed treatment with a second-line agent after disease progression is also acceptable. Recent Data: Seven randomized controlled trials of carboxyaminoimidazole, docetaxel, erlotinib, gefitinib, gemcitabine, and pemetrexed have evaluated outcomes in patients who received an immediate, non-cross resistant alternative therapy (switch maintenance) after first-line therapy. Recommendation: In patients with stage IV NSCLC, first-line cytotoxic chemotherapy should be stopped at disease progression or after four cycles in patients whose disease is stable but not responding to treatment. Two-drug cytotoxic combinations should be administered for no more than six cycles. For those with stable disease or response after four cycles, immediate treatment with an alternative, single-agent chemotherapy such as pemetrexed in patients with nonsquamous histology, docetaxel in unselected patients, or erlotinib in unselected patients may be considered. Limitations of this data are such that a break from cytotoxic chemotherapy after a fixed course is also acceptable, with initiation of second-line chemotherapy at disease progression.

UR - http://www.scopus.com/inward/record.url?scp=80053639884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053639884&partnerID=8YFLogxK

U2 - 10.1200/JCO.2010.34.2774

DO - 10.1200/JCO.2010.34.2774

M3 - Article

VL - 29

SP - 3825

EP - 3831

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 28

ER -